Unique Wealth Strategies LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Unique Wealth Strategies LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 37,134 shares of the biopharmaceutical company’s stock, valued at approximately $1,069,000.

A number of other large investors have also modified their holdings of PFE. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its stake in Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Pfizer by 30.9% in the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after buying an additional 5,678,004 shares in the last quarter. Finally, California Public Employees Retirement System lifted its position in shares of Pfizer by 0.6% during the 3rd quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after buying an additional 101,256 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6 %

PFE stock traded up $0.14 during midday trading on Friday, reaching $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The business’s 50-day simple moving average is $26.96 and its 200-day simple moving average is $28.42. The stock has a market cap of $143.83 billion, a PE ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s dividend payout ratio is 466.67%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.